首页> 外文期刊>Pharmacoepidemiology and drug safety >Population antibiotic susceptibility for Streptococcus pneumoniae and treatment outcomes in common respiratory tract infections.
【24h】

Population antibiotic susceptibility for Streptococcus pneumoniae and treatment outcomes in common respiratory tract infections.

机译:肺炎链球菌的人群抗生素敏感性和常见呼吸道感染的治疗结果。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: Antibiotic-resistant Streptococcus pneumoniae potentially threatens the successful treatment of common respiratory tract infections (RTIs); however, the relationship between antibiotic resistance and treatment outcomes remains unclear. We aimed to test the hypothesis that higher in vitro penicillin and erythromycin nonsusceptibility levels among clinical isolates of S. pneumoniae are associated with higher risk of treatment failure in suppurative acute otitis media (AOM), acute sinusitis, and acute exacerbation of chronic bronchitis (AECB). METHODS: We conducted a population-level analysis using treatment outcomes data from a national, managed-care claims database, and antibiotic susceptibility data from a national repository of antimicrobial susceptibility results between 1997 and 2000. Treatment outcomes in patients with suppurative AOM, acute sinusitis, or AECB receiving selected macrolides or beta-lactams were assessed. Associations between RTI-specific treatment outcomes and antibiotic nonsusceptibility were determined using Spearman correlation coefficients with condition-specific paired outcome and susceptibility data for each region and each year. RESULTS: There were 649 552 available RTI outcomes and 7252 susceptibility tests performed on S. pneumoniae isolates. There were no statistically significant trends across time for resolution proportions following treatment by either beta-lactams or macrolides among any of the RTIs. Correlation analyses found no statistically significant association between S. pneumoniae susceptibility and RTI treatment outcomes apart from a significant positive association between of erythromycin nonsusceptibility in ear isolates and macrolide treatment resolution for suppurative AOM. CONCLUSION: On the population level, in vitro S. pneumoniae nonsusceptibility to macrolide or beta-lactam antibiotics was not associated with treatment failure in conditions of probable S. pneumoniae etiology.
机译:目的:耐药性肺炎链球菌可能威胁到常见呼吸道感染(RTIs)的成功治疗。然而,抗生素耐药性与治疗效果之间的关系仍不清楚。我们旨在检验以下假设:在临床分离的肺炎链球菌中,较高的青霉素和红霉素非敏感性水平与化脓性急性中耳炎(AOM),急性鼻窦炎和慢性支气管炎(AECB)急性加重的治疗失败风险较高相关)。方法:我们使用来自国家管理医疗索赔数据库的治疗结果数据以及来自国家抗菌药物敏感性结果的国家知识库的抗生素敏感性数据进行了人群水平分析,研究范围为化脓性AOM,急性鼻窦炎患者的治疗结果(1997年至2000年)。 ,或评估接受选定大环内酯类或β-内酰胺类药物的AECB。使用Spearman相关系数以及每个地区和每年的特定条件配对结果和敏感性数据,确定RTI特异性治疗结果与抗生素非敏感性之间的关联。结果:对肺炎链球菌分离物进行了649552次RTI结果和7252次药敏试验。在任何RTI中,使用β-内酰胺类或大环内酯类药物治疗后,解决比例在整个时间上均无统计学上的显着趋势。相关分析发现,除了分离株中红霉素对药敏性与大环内酯类药物治疗化脓性AOM的显着正相关外,肺炎链球菌易感性与RTI治疗结果之间无统计学意义的相关性。结论:在人群水平上,在可能的肺炎链球菌病因条件下,体外肺炎链球菌对大环内酯类药物或β-内酰胺类抗生素的不敏感性与治疗失败无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号